2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12788A
    (S)-PF-04449613 99.85%
    (S)-PF-04449613 is the left-handed isomer of PF-04449613 (HY-12788). PF-04449613 is a selective PDE9A inhibitor with an IC50 of 22 nM. PF-04449613 improves motor learning ability in a mouse model.
    (S)-PF-04449613
  • HY-128371
    2-​Methylhexanoic acid 4536-23-6 98.0%
    2-methylhexanoic acid is a medium-chain fatty acid and is used as flavouring.
    2-​Methylhexanoic acid
  • HY-128402
    P2X3-IN-1 2823331-49-1 98%
    P2X3-IN-1 (example 7) is an inhibitor of P2X3 receptor. P2X3-IN-1 can be used for neurogenic diseases research.
    P2X3-IN-1
  • HY-129030
    BDZ-g 732278-52-3 98.0%
    BDZ-g is a potent, selective antagonist of AMPA receptor. BDZ-g has the potential for the research of various neurological disorders involving excessive activity of AMPA receptors.
    BDZ-g
  • HY-129801
    N-Ethyl Hexylone hydrochloride 27912-41-0 ≥99.0%
    N-Ethyl Hexylone hydrochloride is an analogue of methylone and other beta-keto methylenedioxyamphetamines.
    N-Ethyl Hexylone hydrochloride
  • HY-129824
    3-Methyl orsellinic acid 4707-46-4
    3-Methyl orsellinic acid is the fungal metabolite. 3-Methyl orsellinic acid can be used for synthesis of tripodalsporormielones AeC, and exhibits potential in researches related to memory and cognition.
    3-Methyl orsellinic acid
  • HY-12987R
    Pimozide (Standard) 2062-78-4 99.81%
    Pimozide (Standard) is the analytical standard of Pimozide. This product is intended for research and analytical applications. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.
    Pimozide (Standard)
  • HY-12987S
    Pimozide-d4 1803193-57-8 99.2%
    Pimozide-d4 is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.
    Pimozide-d4
  • HY-129923
    (R)-Omeprazole sodium 161796-77-6 98.07%
    (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
    (R)-Omeprazole sodium
  • HY-130419
    (±)13(14)-EpDPA 895127-64-7
    (±)13(14)-EpDPA (13,14-EpDPE) is the product of the reaction of cytochrome P-450 epoxygenase with Docosahexaenoic Acid (DHA).(±)13(14)-EpDPA has antihyperalgesic and vasorelaxative activities.
    (±)13(14)-EpDPA
  • HY-13058B
    (R)-ADX-47273 851881-59-9 99.00%
    (R)-ADX-47273 is a potent mGluR5 positive allosteric modulator, with an EC50 of 168 nM for potentiation .
    (R)-ADX-47273
  • HY-13101B
    (S)-MCOPPB 1108147-70-1 98.97%
    (S)-MCOPPB is the S-form of MCOPPB (HY-13101). MCOPPB is an orally active and selective agonist of Nociceptin/Orphanin FQ-Receptor. MCOPPB inhibits signaling through the NOP receptor in the mouse brain. MCOPPB can be used for anxiety disorders study.
    (S)-MCOPPB
  • HY-131139
    Ganglioside GD3 disodium salt 497932-19-1 98%
    Ganglioside GD3 disodium salt is an acidic glycosphingolipid. Ganglioside GD3 disodium salt inhibits the proliferation of cancer cells, affects the opening of the mitochondrial permeability transition pore (PTPC), induces apoptosis and activates caspase family. Ganglioside GD3 disodium salt can be used in research about cancer and neurodegenerative diseases.
    Ganglioside GD3 disodium salt
  • HY-131289
    LY3020371 1377615-75-2 98%
    LY3020371 is a potent and selective antagonist of glutamate (mGlu) 2/3 receptor, with Kis of 5.26 and 2.50 nM for hmGluR2 and hmGluR3, respectively. LY3020371 can be used for the research of depression.
    LY3020371
  • HY-131413
    O-Desmethyl Galanthamine 60755-80-8 99.70%
    O-Desmethyl Galanthamine (Sanguinine) is galanthamine-type alkaloid. O-Desmethyl Galanthamine is an acetylcholinesterase (AChE) inhibitor, with an IC50 1.83 μM.
    O-Desmethyl Galanthamine
  • HY-131693
    γ-Acetylenic GABA 57659-38-8 98%
    γ-Acetylenic GABA (4-Aminohex-5-ynoic acid) is an irreversible inhibitor of GABA-transaminase. γ-Acetylenic GABA can increase the concentration of GABA in rat brain. γ-Acetylenic GABA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    γ-Acetylenic GABA
  • HY-131885
    RuBi-Glutamate hexafluorophosphate sodium 2417096-44-5
    RuBi-Glutamate hexafluorophosphate sodium is a novel cage glutamate compound based on ruthenium photochemistry. RuBi-Glutamate hexafluorophosphate sodium can be excited at visible wavelengths and release glutamate after single or two-photon excitation. It has high quantum efficiency and can be used at low concentrations, partially avoiding the blocking of GABA energy transmission by other cage compounds. Two-photon release of RuBi-Glutamate hexafluorophosphate sodium has high spatial resolution and produces a physiodynamic excitatory response in a single dendritic spine.
    RuBi-Glutamate hexafluorophosphate sodium
  • HY-131941
    SJM-3 1234977-97-9
    SJM-3 is a positive allosteric modulator of different isoforms of the GABAA receptor. SJM-3 binds at the high-affinity benzodiazepine binding site at the α+/γ- subunit interface.
    SJM-3
  • HY-132246
    WWL123 analogue-1 1338575-41-9 98.04%
    WWL123 analogue-1 is an analogue of WWL123. WWL123 is a potent and selective ABHD6 inhibitor with an IC50 of 430 nM. WWL123 crosses the blood-brain-barrier and inhibits ABHD6 in brain parenchyma. ABHD6 blockade by WWL123 exerts an antiepileptic effect in Pentylenetetrazole (PTZ)-induced epileptiform seizures and spontaneous seizures in R6/2 mice.
    WWL123 analogue-1
  • HY-132268
    Cav 2.2 blocker 2 1204535-44-3 98.51%
    Cav 2.2 blocker 2 is a Cav2.2 calcium channel blocker extracted from patent WO2017046581A1, compound 1. Cav 2.2 blocker 2 can reverses hyperalgesia associated with an injury or inflammation in conjunction with the opioid.
    Cav 2.2 blocker 2
Cat. No. Product Name / Synonyms Application Reactivity